European Medicines Agency Updates Seasonal Flu Vaccine Guidance - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

European Medicines Agency Updates Seasonal Flu Vaccine Guidance


The European Medicines Agency released an update to its guidance for the annual strain change of influenza vaccines to reflect current knowledge. The change makes the guidance document consistent with the approach taken by other global regulatory authorities. An improved system that allows strengthened and sustainable monitoring of an influenza vaccine’s performance over the years in a real-life setting is introduced in the guidance.

The guidance states that vaccine manufacturers will be required to submit for each vaccine appropriate measures for proactive surveillance of the safety and effectiveness to regulatory authorities for review. The requirement is for the influenza season 2014-2015 onwards. With the new system in place, EMA will no longer require routine submission of clinical trials for annual strain-change updates. An interim guidance will be published by March 2014 and will address the principles of safety monitoring commitments that should form part of the proactive surveillance.

Source: European Medicines Agency

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race

Click here